105 results about "Upper third" patented technology

The present invention relates to personal care foaming and cleansing products comprising multiple phases which are separate and distinct and comprise at least one surfactant solution having a density or specific gravity of approximately 1.0. In a two-phase composition, a second separated phase may comprise cosmetically acceptable oily materials as emollients/conditioners having a density greater than that of the surfactant solution. In a three phase composition, an additional phase may comprise a low density emollient/conditioning compound(s) as an upper third phase. Thus, two, three or even four phase foaming bath products, shampoos and skin cleansers can be produced that can be differentially colored to enhance the visual separation of the layers and will provide foaming, cleaning, conditioning and emolliency in a unique and attractive manner.

The present invention relates to intranasally administering a pharmaceutical composition comprising curcumin to an upper third of a nasal cavity of the mammal, wherein the curcumin is absorbed through a nasal mucosa and transported to the brain of the mammal.

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.

The invention relates to a surveillance video oriented bearded face detection method. The method mainly used for processing the surveillance videos and comprises the following steps: reading a video file into a computer, decoding, and obtaining a region with human upper body moving targets by using an improved background subtraction method and a human upper body HOG classifier; then, aiming at the upper one third part of the human upper body moving region, detecting the possible face region in the part by adopting a face Haar classifier, and intercepting the lower half part of the face region as a beard detection region; finally, carrying out scale normalization for the region, then calculating the horizontal texture complexity, and judging whether beards exist or not. The method utilizes the motion feature and the morphological feature of the surveillance video oriented bearded faces, can reliably detect the bearded face targets in the walking and running front upright bodies.

A method for producing a semiconductor structure including preparing a semiconductor substrate, and generating a lower first, a middle second and an upper third masking layer on a surface of the semiconductor substrate. The method further includes forming at least one first window in the upper third masking layer, structuring the middle second masking layer using the first window for transferring the first window, structuring the lower first masking layer using the first window for transferring the first window, and enlarging the first window to form a second window. The method for further includes restructuring the middle second masking layer using the second window for transferring the second window, structuring the semiconductor substrate, using the structured lower third masking layer, restructuring the lower first masking layer using the second window, and restructuring the semiconductor substrate using the restructured lower third masking layer.

Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper one-third of a mammal's, preferably a human, nasal cavity, thereby enabling the administered at least one effective amount of insulin to bypass the patient's blood-brain barrier and be directly delivered to the patient's CNS. Another embodiment comprises utilizing vasoconstrictors to enhance targeting of an effective amount of insulin to the CNS while reducing non-target exposure.

Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The present invention provides these advantages by administering at least an effective amount of insulin and/or pharmaceutical composition(s) thereof, to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and delivering an effective amount of insulin and/or pharmaceutical compound(s) thereof directly to the CNS. Further methods comprise administering an at least an effective amount of therapeutic agents to the amniotic fluid surrounding a fetus with a treatable neurologic agent or a preventable neurologic condition. For example, administering the at least effective amount of insulin to the amniotic fluid of a fetus with a mother diagnosed with gestational diabetes may prevent the fetus from developing Social Communication Disorder or autism.

The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.

This invention relates to a golfing putter and, more particularly, a golfing putter (1) for helping golfers strike a golf ball (17) consistently without inducing backspin on the ball. The golfing putter (1) comprises a head (2) fixed to a shaft (3). The head (2) has a front face (7) for striking the golf ball (17), and an upper face (6) disposed in use towards the golfer. The vertical centre of mass (8) is behind an upper portion of the front face (7) of the head (2). The head (2) has at least in a central portion (35) of the front face (7) an inverted L-shaped cross-section with the top face (6) forming an upper arm (36) of the L-shape and the front face (7) forming the front arm (37) of the L-shape. The front arm (37) is thinner than the top arm (36). The head therefore has a vertical centre of mass (8) behind an upper third of the front face (7) of the head (2) above the impact point with the golf ball (17).

Apparatus for evaporating calciferous water by means of electrical heating includes an injection nozzle connected to a spray hose arranged in the upper third of an evaporator immediately above a thermostat that is disposed on the bottom side of the evaporator, the distance between the injection nozzle and the thermostat being less than 15 mm, the steam hose being connected to the evaporator via a steam connector, the steam connector having an inside diameter of at least 5 mm, and the evaporator at an angle of inclination of 5° to 10°.

The present invention is to provide a thin film magnetic head intended to increase precision of and to narrow a width which determines a track width of a write thin film magnetic head and to supply a stably high output substantially free from write blurring on a disk, and a method for manufacturing the same. The thin film magnetic head consisting of a magnetic circuit comprising a read head to read information, a lower magnetic film, a magnetic gap and an upper magnetic film formed with a magnetic gap between it and the lower magnetic film; and of a write head comprising a coil positioned between the upper magnetic film and the lower magnetic film and an insulating film for insulting the coil and the upper magnetic film from each other, wherein the upper magnetic film is configured of an upper first magnetic film, an upper second magnetic film and an upper third magnetic film, and the upper first magnetic film is connected to the upper third magnetic film via the upper second magnetic film.

The invention relates to a vehicle seat with a seat part and with a seat back part for supporting a driver of the vehicle in the sitting position on the vehicle seat, wherein the vehicle seat is characterized by an additional vehicle driver's torso support device which can be disposed outside the seat part and the seat back part and which can be temporarily disposed at least partially in an otherwise seat-free torso support region at the level of or above the upper third of the seat back part in front of the seat back part and laterally off-center on the seat back part, in order to provide support, laterally off-center of the seat back part, at least at the level of the shoulder or chest region of the driver who is sitting on the vehicle seat when he adopts a seated working posture oriented to the side or backwards, wherein the additional vehicle driver's torso support device is disposed so as to be movable by a moving device from a parked position into an additional torso support position in the otherwise seat-free torso support region.